Search

Showing total 182 results

Search Constraints

Start Over You searched for: Search Limiters Full Text Remove constraint Search Limiters: Full Text Topic cervix uteri diseases Remove constraint Topic: cervix uteri diseases
182 results

Search Results

1. TUMOR MARKERS IN OVARIAN CANCER.

2. Role of miR-221/222 in Tumor Development and the Underlying Mechanism.

3. Skin metastasis from squamous cell carcinoma of the cervix to the lower extremities: Case report and review of the literature.

4. COLPOSCOPIC EXAMINATION IN CYTOLOGY NEGATIVE WOMEN WHO TESTED POSITIVE FOR NON-16/18 HPV TYPES.

5. Post-conization surveillance in an organized cervical screening program with more than 23,000 years of follow-up.

6. Vaginal Septoplasty in Septate Uterus with Double Cervix.

7. Cervical cancer: a meta-analysis, therapy and future of nanomedicine.

8. Surgical Treatment for Early Cervical Cancer in the HPV Era: State of the Art.

9. A COCKTAIL OF MCM2 AND TOP2A, P16INK4A AND KI-67 AS BIOMARKERS FOR THE IMPROVED DIAGNOSIS OF CERVICAL INTRAEPITHELIAL LESION.

10. Urothelial cells in smears from cervix uteri.

11. Association between secondhand smoke exposure and abnormal cervical cytology: A one-to-one matched case control study.

12. HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3.

13. The Role of Micronutrients in Human Papillomavirus Infection, Cervical Dysplasia, and Neoplasm.

14. Molecular triage of cervical screening samples in women 55–59 years of age: a pilot study.

17. Recommendations of the Polish Society of Gynaecologists and Obstetricians, Polish Paediatric Society, Polish Society of Family Medicine, Polish Society of Vaccinology, Polish Society of Oncological Gynaecology, and Polish Society of Colposcopy and Cervical Pathophysiology on prophylactic vaccinations against infections with human papillomaviruses in Poland.

18. Management in case of pathological changes of the uterine cervix during pregnancy.

19. Identification and Validation of Human Papillomavirus Encoded microRNAs.

20. Ultrasonographic identification of the anatomical landmarks that define cervical lymph nodes spaces.

21. Biomarkers of Cervicovaginal Inflammation for the Assessment of Microbicide Safety.

22. Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis.

23. T Cell Receptor Repertoires Acquired via Routine Pap Testing May Help Refine Cervical Cancer and Precancer Risk Estimates.

24. Identification of a tumor microenvironment-related gene signature to improve the prediction of cervical cancer prognosis.

25. Topographic distribution of lymph node metastasis in patients with stage IB1 cervical cancer: an analysis of 8314 lymph nodes.

26. Combination of histochemical analyses and micro-MRI reveals regional changes of the murine cervix in preparation for labor.

27. TOP2A/MCM2, p16INK4a, and cyclin E1 expression in liquid-based cytology: a biomarkers panel for progression risk of cervical premalignant lesions.

28. Development and validation of an artificial intelligence system for grading colposcopic impressions and guiding biopsies.

29. Evaluating smartphone strategies for reliability, reproducibility, and quality of VIA for cervical cancer screening in the Shiselweni region of Eswatini: A cohort study.

30. Women's appraisal, interpretation and help-seeking for possible symptoms of breast and cervical cancer in South Africa: a qualitative study.

31. Cervical cancer in low and middle-income countries.

32. Necrotizing Fasciitis of the Cervical Region following Extravasation Injury.

33. Retrospective Review of Loop Electrosurgical Excision Procedure (LEEP) Outcomes at a Tertiary Hospital in Zambia.

34. Morphological Characteristics and Clinical Significance of Different Types of Tumor Vessels in Patients with Stages I-IIA of Squamous Cervical Cancer.

35. Classification of cervical neoplasms on colposcopic photography using deep learning.

36. Novel use of fine needle aspiration (FNA) biopsy to diagnose cervical cancer in a low‐resource setting: A case series Morovia, Liberia.

37. Acceptability of HPV screening among HIV-infected women attending an HIV-dedicated clinic in Abidjan, Côte d'Ivoire.

38. HIV and development of epithelial cell abnormalities in women with prior normal cervical cytology in Nigeria.

39. Efficient mutation screening for cervical cancers from circulating tumor DNA in blood.

40. Factors affecting cervical cancer screening uptake, visual inspection with acetic acid positivity and its predictors among women attending cervical cancer screening service in Addis Ababa, Ethiopia.

41. Gynaecological cancer in Caribbean women: data from the French population-based cancer registries of Martinique, Guadeloupe and French Guiana (2007-2014).

42. Tumor immune microenvironment in cancer patients with leukocytosis.

43. Predictors of Precancerous Cervical Lesions Among Women Screened for Cervical Cancer in Bahir Dar Town, Ethiopia: A Case–Control Study.

44. miR-4429 Regulates the Proliferation, Migration, Invasion, and Epithelial-Mesenchymal Transition of Cervical Cancer by Targeting FOXM1.

45. Combined external pelvic chemoradiotherapy and image-guided adaptive brachytherapy in treatment of advanced cervical carcinoma: experience from a single institution.

46. Cervical Dysplasia, Infection, and Phylogeny of Human Papillomavirus in HIV-Infected and HIV-Uninfected Women at a Reproductive Health Clinic in Nairobi, Kenya.

47. Potential risks in sentinel lymph node biopsy for cervical cancer: a single-institution pilot study.

48. MIAT inhibits proliferation of cervical cancer cells through regulating miR-150-5p.

49. DSG2 expression is correlated with poor prognosis and promotes early-stage cervical cancer.

50. Factors Associated with Treatment Uptake Among Women with Acetic Acid/Lugol's Iodine Positive Lesions of the Cervix in Cameroon.